Blood Test Could Predict Heart Disease and Diabetes Risk Through Endothelial Damage
New biomarker soluble endoglin shows promise for early detection of cardiovascular and metabolic disorders in blood tests.
Summary
Scientists have identified a promising new biomarker called soluble endoglin (sENG) that could help predict cardiovascular and metabolic diseases. This comprehensive analysis of 16 studies involving over 2,100 people found that sENG levels in blood are significantly higher in patients with type 1 diabetes, type 2 diabetes, and heart failure compared to healthy individuals. The biomarker reflects damage to the endothelium, the inner lining of blood vessels that plays a crucial role in cardiovascular health. Higher sENG levels indicate endothelial dysfunction, an early step in developing atherosclerosis and other vascular complications. This discovery could lead to earlier detection and intervention for these conditions, potentially improving long-term health outcomes.
Detailed Summary
Endothelial dysfunction, damage to the inner lining of blood vessels, is a critical early step in developing cardiovascular disease and metabolic disorders. Early detection of this damage could revolutionize preventive medicine and extend healthy lifespan by enabling timely interventions.
Researchers conducted the first comprehensive meta-analysis examining soluble endoglin (sENG) as a biomarker for endothelial dysfunction. They analyzed 16 studies encompassing 2,113 participants, including 1,391 patients with various cardiovascular and metabolic conditions and 722 healthy controls. The team searched major medical databases through August 2025, focusing on conditions like atherosclerotic cardiovascular disease, diabetes, hypertension, and heart failure.
The results revealed significantly elevated sENG levels across all studied conditions, with an overall increase of 0.92 ng/mL compared to healthy controls. Most notably, type 2 diabetes patients showed the highest elevation at 1.98 ng/mL, followed by type 1 diabetes at 0.99 ng/mL, and heart failure at 1.06 ng/mL. These findings suggest sENG could serve as an early warning system for vascular damage.
For longevity-focused individuals, this research offers hope for better disease prediction and prevention. A simple blood test measuring sENG could potentially identify cardiovascular and metabolic risks years before symptoms appear, allowing for lifestyle modifications, targeted therapies, and closer monitoring. However, more research is needed to establish clinical cutoff values and validate sENG's predictive accuracy in diverse populations before it becomes a routine screening tool.
Key Findings
- Soluble endoglin levels were 0.92 ng/mL higher in patients with endothelial dysfunction disorders
- Type 2 diabetes showed the highest elevation at 1.98 ng/mL above normal levels
- Type 1 diabetes and heart failure patients also showed significantly elevated biomarker levels
- First meta-analysis to validate soluble endoglin as a cardiovascular risk biomarker
- Blood test could enable earlier detection of vascular damage before symptoms appear
Methodology
Meta-analysis of 16 studies with 2,113 total participants (1,391 patients, 722 controls). Researchers searched PubMed, Scopus, and Web of Science databases through August 2025, using Newcastle-Ottawa Scale for quality assessment.
Study Limitations
Study limited to specific conditions and may not represent all populations. Clinical cutoff values for diagnostic use haven't been established, and more validation studies are needed before routine clinical implementation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.